26 completed, 2 active not recruiting, 2 unknown, 1 terminated. 31 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 31 | Completed 26, Active not recruiting 2, Unknown 2, Terminated 1 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Pasteurellaceae Infections: new trials by email Literature Review of Pasteurellaceae Infections trials Research Report on Pasteurellaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine Haemophilus influenzae serotype a vaccine candidate, Saline (as a placebo) - Haemophilus Influenzae, Haemophilus Influenzae Type a | Phase 2 | Active not recruiting | InventVacc Biologicals Inc. | 47 | 2026-04-29 | 2026-08-03 |
| A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid Hexavalent Diphtheria-tetanus-whole Cell Pertussis-hepatitis B-poliovirus-Haemophilus Influenzae Type b Conjugate (DTwP-HepB-IPV-Hib) Vaccine, in Healthy Infants as Primary Series LBVD, Pentavalent vaccine and Inactivated Polio vaccine - Diphtheria, Tetanus | Phase 2 / Phase 3 | Active not recruiting | LG Chem | 1186 | 2025-05-30 | 2026-09-03 |
| Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age LR20062, DTaP-HepB-IPV-Hib vaccine - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2024-10-02 | 2024-10-01 |
| Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants DTwP-HepB-Sabin IPV-Hib, Pentavalent vaccine and Salk IPV - Diphtheria, Tetanus | Phase 2 | Unknown | LG Chem | 336 | 2019-11-01 | 2019-09-06 |
| Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series LBVD (Hexavalent vaccine), Pentavalent vaccine and Inactivated Polio vaccine (Sabin strains) - Diphtheria, Tetanus | Phase 2 / Phase 3 | Completed | LG Chem | 60 | 2018-07-18 | 2026-09-03 |
| Exploratory Clinical Study of MT-2301 Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV, Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV, Haemophilus influenza type b conjugate vaccine + DPT-IPV - Haemophilus Influenza Type b | Phase 2 | Completed | Tanabe Pharma Corporation | 154 | 2014-04-01 | 2026-03-17 |
| Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants Pneumococcal conjugate vaccine GSK2830929A, Pneumococcal conjugate vaccine GSK2830930A, Synflorix™ - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 953 | 2012-07-11 | 2019-07-16 |
| Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa, Prevenar 13, GSK217744 - Acellular Pertussis, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 657 | 2011-10-14 | 2020-07-17 |
| Impact of GSK Biologicals' 2189242A Vaccine on Nasopharyngeal Carriage, Safety & Immunogenicity in Children & Infants Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix™ - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 1320 | 2011-02-09 | 2019-06-19 |
| Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744) Infanrix hexa™, Prevenar 13®, GSK217744 - Tetanus, Poliomyelitis | Phase 2 | Completed | GlaxoSmithKline | 721 | 2010-12-09 | 2018-08-20 |
| Safety & Immunogenicity of Pneumococcal Vaccine 2189242A Co-administered With DTPa-HBV-IPV/Hib in Healthy Infants Pneumococcal vaccine GSK 2189242A (LD formulation 1), Pneumococcal vaccine GSK 2189242A (HD formulation 2), Synflorix - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 576 | 2010-09-27 | 2019-05-29 |
| Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Dose GSK2202083A vaccine, Infanrix hexa™, Menjugate™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 391 | 2010-08-18 | 2020-01-21 |
| Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants GSK2202083A vaccine, Prevenar 13®, Infanrix hexa™ - Tetanus, Hepatitis B | Phase 2 | Completed | GlaxoSmithKline | 480 | 2010-05-17 | 2018-08-20 |
| Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers GSK2036874A vaccine, Zilbrix™/Hib vaccine, Poliorix™ - Haemophilus Influenzae Type b, Tetanus | Phase 2 | Completed | GlaxoSmithKline | 312 | 2010-05-13 | 2019-10-01 |
| Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination Pneumococcal vaccine GSK2189242A (formulation 1), Pneumococcal vaccine GSK2189242A (formulation 2), Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3) - Infections, Streptococcal | Phase 2 | Completed | GlaxoSmithKline | 257 | 2009-11-24 | 2020-11-05 |
| Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age GSK2202083A vaccine, 10-valent pneumococcal vaccine (GSK 1024850A), Infanrix hexa™ - Tetanus, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 421 | 2009-08-13 | 2020-01-03 |
| Nontypeable H. Influenzae in Healthy Adults NTHi Strain 2019 - Haemophilus Influenzae (NTHI) | Phase 1 / Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2009-08-01 | 2013-04-11 |
| Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants GSK2197870A, Prevenar™, Menitorix™ - Neisseria Meningitidis, Haemophilus Influenzae Type b | Phase 2 | Completed | GlaxoSmithKline | 284 | 2009-06-24 | 2018-06-06 |
| Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age. GSK2202083A vaccine, Infanrix hexa, Menjugate - Tetanus, Poliomyelitis | Phase 2 | Terminated | GlaxoSmithKline | 16 | 2009-04-01 | 2018-06-06 |
| Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine Infanrix Hexa - Acellular Pertussis, Diphtheria | Phase 2 | Completed | GlaxoSmithKline | 403 | 2008-02-01 | 2018-06-06 |
Showing 20 of 31. Sign in to see all of them.
Haemophilus Infections (31) · Diphtheria (19) · Hepatitis B (19) · Tetanus (19) · Poliomyelitis (16) · Whooping Cough (8) · Streptococcal Infections (4) · Meningococcal Infections (1)
Bacterial Infections (31) · Bacterial Infections and Mycoses (31) · Gram-Negative Bacterial Infections (31) · Infections (31) · Gram-Positive Bacterial Infections (23) · Actinomycetales Infections (19) · Blood-Borne Infections (19) · Clostridium Infections (19) · Communicable Diseases (19) · Corynebacterium Infections (19) · DNA Virus Infections (19) · Digestive System Diseases (19) · Hepadnaviridae Infections (19) · Hepatitis (19)
diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (12) · 13-valent pneumococcal vaccine (5) · Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate (4) · Heptavalent Pneumococcal Conjugate Vaccine (4) · PHiD-CV vaccine (4) · Hib-MenCY-TT vaccine (3) · Vaccines, Combined (3) · DTPa-HBV-IPV combined vaccine (2) · Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine (2) · Poliovirus Vaccine, Inactivated (2) · 10-valent pneumococcal vaccine (1) · Chickenpox Vaccine (1) · DTP-IPV-Hib vaccine (1) · DTaP-IPV-HB-PRP-T vaccine (1) · Hiberix (1)
GlaxoSmithKline (22) · LG Chem (4) · Sanofi Pasteur, a Sanofi Company (2) · InventVacc Biologicals Inc. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Tanabe Pharma Corporation (1)
Germany (5) · Finland (4) · Philippines (4) · Poland (4) · Canada (3) · Czechia (3) · Australia (2) · Dominican Republic (2) · United States (2) · Argentina (1) · Belgium (1) · France (1) · Japan (1) · Slovakia (1) · South Korea (1)
Edison Alberto, MD (1) · Joanne M Langley, MD (1) · Josefina Carlos, MD (1) · Takashi Nakano, M.D., Ph.D. (1)
PMID 28340322, PMID 20657177, PMID 21372751, PMID 23241989, PMID 24346596
2009 (2), 2016 (1)